Review of Nexavar data presented at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO)

June 1 - 5, 2007
Chicago, Illinois

Results from various clinical studies including a pivotal Phase III trial in patients with advanced hepatocellular carcinoma, or primary liver cancer with Nexavar® (sorafenib) tablets were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO).

Monday, June 4, 2007 at 2:00 p.m. CEST:
Investor Conference Call - Review of Nexavar Data presented at ASCO

MP3 audio recording (presentation and discussion)

Fact Sheets
Nexavar Fact Sheet
Download ( PDF, 87 KB ) collect
Renal Cell Carcinoma Fact Sheet
Download ( PDF, 52 KB ) collect
Hepatocellular Carcinoma Fact Sheet
Download ( PDF, 62 KB ) collect
Melanoma Fact Sheet
Download ( PDF, 55 KB ) collect
Non-Small Cell Lung Cancer Fact Sheet
Download ( PDF, 54 KB ) collect

Abstract on Nexavar (Sorafenib) at ASCO 2007

Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial) - abstract LBA1

Clinical trials information:

American Cancer Society:

American National Cancer Institute:

Information on kidney cancer:

Information on liver cancer:

Information on melanoma:

Information on lung cancer:

Information on cancer incidence, prevalence and mortality (GLOBOCAN):

Last updated: January 09, 2014 Copyright © Bayer AG